SENORES PHARMACEUTICALS LIMITED
₹1,133.60-₹84.95 (-7.0%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹3,750 Cr
- P/E
- 307.0x
- EV / EBITDA
- 545.5x
- Revenue
- ₹39.0 Cr
- Net margin
- 2.9%
- ROCE
- 0.0%
Price chart
Technical chartScreen technicals →+46.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -18.1%
- 3M
- -12.3%
- 6M
- +26.1%
- 1Y
- +46.1%
- 5Y
- +97.8%
52-week range
Day change -₹84.95 (-7.0%) from ₹1,219 to ₹1,134 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in SENORES, bought on each weekday since 2024.
AI Summary
Indian StockStrengths1
- Revenue grew 14.7% YoY
Concerns1
- Low return on equity of 0.6%
Rule-based from financial data. Not advice.
About the company
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally.
Read moreShow less
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
- Sector
- Healthcare
- Shares outstanding
- 4.6 Cr shares
- ISIN
- INE0RB801010
- BSE code
- 544319
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹3,750 Cr
- P/E
- 307.0x
- P/B
- 5.2x
- EV / EBITDA
- 545.5x
- EV / Sales
- 112.3x
- P/S
- 110.3x
- Earnings yield
- 0.3%
- 52-week high
- ₹1,552.80
- 52-week low
- ₹711.50
Profitability
- Operating margin
- 0.0%
- Net margin
- 2.9%
- EBITDA margin
- 20.6%
- ROE
- 0.6%
- ROCE
- 0.0%
- ROA
- 0.3%
- Dividend payout
- 0.0%
- Tax rate
- 60.0%
- Other income, % of PBT
- 350.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹39.0 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.7%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹7.00 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 40.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 300.0%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹19.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -55.8%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹349 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 155.4%
Solvency and efficiency
- Current ratio
- 14.35
- Debt / Equity
- 0.60
- Debt / Assets
- 0.35
- Debt / EBITDA
- 14.43
- Financial leverage
- 1.69
- CFO / Net profit
- -19.00
- Cash / Market cap
- 4.3%
- Cash per share
- ₹35.12
- Asset turnover
- 0.12
- Fixed asset turnover
- 1.42
- Capital intensity
- 0.71
- Debtor days
- 236 days
- Inventory turnover
- 3.02
- Cash conversion cycle
- 47 days
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Sales | ₹39 Cr |
| Expenses | ₹46 Cr |
| Operating profit | -₹7 Cr |
| Other income | ₹22 Cr |
| Interest | ₹7 Cr |
| Depreciation | ₹3 Cr |
| Profit before tax | ₹5 Cr |
| Tax and other | ₹1 Cr |
| Net profit | ₹4 Cr |
Revenue and net profit
Revenue grew 14.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹8 Cr | ₹1 Cr |
| FY2022 | ₹14 Cr | ₹1 Cr |
| FY2023 | ₹12 Cr | ₹1 Cr |
| FY2024 | ₹34 Cr | ₹1 Cr |
| FY2025 | ₹39 Cr | ₹4 Cr |
Cash flows
FY2025: -₹20.0 Cr from operations, -₹183 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹3 Cr | -₹7 Cr |
| FY2022 | -₹24 Cr | -₹34 Cr |
| FY2023 | -₹43 Cr | -₹48 Cr |
| FY2024 | -₹19 Cr | -₹76 Cr |
| FY2025 | -₹20 Cr | -₹183 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹39 Cr+14.7%1Y
- Net profit
- ₹4 Cr+300.0%1Y
- Cash from operations
- -₹20 Cr
- Free cash flow
- -₹183 Cr
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹39 Cr | -₹7 Cr | — | ₹4 Cr | -₹20 Cr | -₹183 Cr | 0.6% | +14.7% | +300.0% |
Monthly returns
Month-by-month returns of SENORES across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹834 Cr |
| Equity capital | ₹46 Cr |
| Reserves | ₹662 Cr |
| Borrowings | ₹103 Cr |
| Other liabilities | ₹23 Cr |
| Assets | ₹834 Cr |
| Fixed assets | ₹55 Cr |
| Capital work in progress | ₹34 Cr |
| Investments | ₹104 Cr |
| Other assets | ₹641 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
SENORES trades at 307.0x earnings against a peer median of 52.6x (a 484% premium).
Not shown (no positive earnings and no EV / Sales): Dishman Carbogen Amcis Limited, Suven Life Sciences Ltd.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| SENORES PHARMACEUTICALS LIMITEDSENORESthis companyP/E ↑ premium | ₹3,750 Cr | 307.0x | 5.2x | 0.6% | 545.5x |
| Dishman Carbogen Amcis LimitedDCAL | ₹4,132 Cr | — | 1.0x | -1.9% | 67.5x |
| Artemis Medicare Services LimitedARTEMISMED | ₹4,059 Cr | 42.6x | 4.0x | 10.8% | 32.0x |
| Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,008 Cr | 83.0x | 15.1x | 29.4% | 48.1x |
| INNOVA CAPTAB LIMITEDINNOVACAP | ₹3,945 Cr | 51.8x | 4.6x | 9.4% | 34.2x |
| RPG Life Sciences LimitedRPGLIFE | ₹3,806 Cr | 34.2x | 6.9x | 23.5% | 27.7x |
| Indraprastha Medical Corporation LtINDRAMEDCO | ₹3,742 Cr | 21.4x | 5.7x | 25.9% | 17.5x |
| Orchid Pharma LimitedORCHPHARMA | ₹3,739 Cr | 51.8x | 2.8x | — | — |
| Suven Life Sciences Ltd.SUVEN | ₹3,490 Cr | — | 3.3x | -0.9% | -1728.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
SENORES since 1 January, against earlier years.
Historical volatility
SENORES's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 13.0% |
| FY2022 | 9.0% |
| FY2023 | -14.0% |
| FY2024 | 0.0% |
| FY2025 | -19.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹39 Cr |
| Costs | |
| Interest | ₹7 Cr |
| Expenses | ₹46 Cr |
| Operating profitOperating Profit | -₹7 Cr |
| Other income and charges | |
| Profit before tax | ₹5 Cr |
| Tax | |
| Net profitNet Profit | ₹4 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹834 Cr |
| Equity capitalEquity Capital | ₹46 Cr |
| Reserves | ₹662 Cr |
| Borrowings | ₹103 Cr |
| Other liabilitiesOther Liabilities | ₹23 Cr |
| AssetsTotal Assets | ₹834 Cr |
| Fixed assetsFixed Assets | ₹55 Cr |
| Capital work in progressCWIP | ₹34 Cr |
| Investments | ₹104 Cr |
| Other assetsOther Assets | ₹641 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | -₹20 Cr |
| Investing cash flowCash from Investing Activity | -₹163 Cr |
| Financing cash flowCash from Financing Activity | ₹533 Cr |
| Change in cashNet Cash Flow | ₹349 Cr |
Learn while you research
Academy chapters picked for SENORES PHARMACEUTICALS LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 307.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read